- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Evogene (EVGN)
Evogene stock price live, this page displays TASE EVGN stock exchange data. View the EVGN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Evogene real time stock price chart below.
What Is the Evogene Stock Price Today?
The Evogene stock price today is 0.854.
What Is the Stock Symbol for Evogene?
The stock ticker symbol for Evogene is EVGN.
Is EVGN the Same as $EVGN?
$EVGN is a common way to refer to the Evogene ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Evogene Trade On?
Evogene is listed and trades on the Tel Aviv stock exchange.
Is Evogene a Good Stock to Buy?
Determining whether Evogene—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Evogene share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EVGN quote. (ISIN: IL0011050551)
What Is the Evogene Stock Price Today?
The Evogene stock price today is 0.854.
What Is the Stock Symbol for Evogene?
The stock ticker symbol for Evogene is EVGN.
Is EVGN the Same as $EVGN?
$EVGN is a common way to refer to the Evogene ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Evogene Trade On?
Evogene is listed and trades on the Tel Aviv stock exchange.
Is Evogene a Good Stock to Buy?
Determining whether Evogene—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Evogene share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EVGN quote. (ISIN: IL0011050551)
0.854
+0.034(+4.16%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.810
0.859
52 wk Range
0.720
2.420
EVGN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.8100.859
52 wk Range
0.7202.420
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
EVGN Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Form 6K Evogene Ltd. For: 2 April
- Investing.com
- Form 6K Evogene Ltd. For: 2 April
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). The company was incorporated in 1999 and is headquartered in Rehovot, Israel.
Evogene Earnings Call Summary for Q3/2025
- Evogene (EVGN) reported Q3 2025 EPS of -$0.31, beating forecasts of -$0.43 with a 27.91% positive surprise, despite revenue falling to $310,000 from $1.7M year-over-year.
- Net income swung to $5.2M from a loss of $8.2M in Q3 2024, with stock rising 2.56% to $1.20 in pre-market trading despite revenue missing expectations by 46.09%.
- The company completed significant organizational restructuring, reducing operating expenses while maintaining a $16M cash balance supported by asset sales.
- Evogene launched Campus AI targeting pharmaceutical and agricultural markets, with CEO Ofer Haviv highlighting it as 'our main competitive advantage' for driving innovation.
- Management forecasts new pharmaceutical collaborations in early 2026, focusing on strategic partnerships in biotech and pharmaceutical sectors to leverage AI technology for growth.
Last Updated: 11/20/2025, 10:46 AM
Read Full TranscriptCompare EVGN to Peers and Sector
Metrics to compare | EVGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEVGNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.7x | −1.2x | −0.5x | |
PEG Ratio | −0.01 | 0.24 | 0.00 | |
Price / Book | −124.7x | 1.3x | 2.6x | |
Price / LTM Sales | 2.7x | 5.7x | 3.2x | |
Upside (Analyst Target) | 174.4% | 700.0% | 47.6% | |
Fair Value Upside | Unlock | 22.1% | 6.1% | Unlock |
Earnings
Latest Release
Mar 05, 2026
EPS / Forecast
-0.61 / -0.41
Revenue / Forecast
2.28M / 650K
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.